navigation for timely adjuvant therapy for patients with locally advanced hnscc

Conditions: Squamous Cell Carcinoma of Head and Neck

Summary: head and neck cancer squamous cell carcinoma (hnscc) is a disease with poor survival, especially for african americans, despite intense treatment including surgery, radiation, and chemotherapy. delays between surgery and the start of postoperative radiation therapy (port) are common, cause excess mortality, and contribute to worse survival in african americans. our research team has developed ndure (navigation for disparities and untimely radiation therapy), a novel theory-based patient navigation (pn) intervention to decrease delays and racial disparities starting port. in this single-site, open label, single-arm trial, adults with surgically-managed, locally advanced hnscc, will be enrolled in ndure to assess the feasibility and acceptability of ndure as a novel approach to decreasing delays and racial disparities starting port after surgery for hnscc. the investigators will collect information about the accrual rate and ndure completion rate. participants will also complete validated questionnaires at baseline and post-intervention to evaluate the feasibility of outcome assessment for ndure. post-intervention, patients and providers will undergo interviews to obtain in-depth understanding of the content, format, timing, and delivery of ndure to optimize the intervention in preparation for a future multi-site study. ndure could provide the first effective intervention to improve the delivery of timely, equitable port after hnscc surgery, thereby improving survival for patients with hnscc, decreasing racial disparities in mortality, and developing new standards of clinical care.

design: the study design is a single-site, single-arm, trial of ndure (navigation for disparities and untimely radiation therapy) to assess the feasibility and acceptability of this patient navigation (pn) intervention to decrease delays and racial disparities starting postoperative radiation therapy (port) after surgery for hnscc. following screening and informed consent, sociodemographic and oncologic will be prospectively gathered about participants from validated questionnaires and the electronic medical record (emr). participants will undergo 3 sessions of ndure. measures of feasibility (enrollment, dropout, missed pn encounters, navigator caseload, and time allocation) will be assessed during delivery of ndure. questionnaires assessing symptom burden and health-related beliefs will be collected at baseline and post-treatment to assess the feasibility of data collection procedures and monitor completion rates. following completion of ndure, patients with hnscc will complete validated measures of acceptability related to satisfaction with pn. post-ndure qualitative work with patients and providers will help refine the intervention treatment allocation: participants will be enrolled into ndure delivery of intervention: ndure is a navigation-based, multilevel intervention targeting barriers to timely, guideline-adherent port at the patient-, healthcare team-, and organization-levels. ndure consists of 6 key functions including (1) improve patient knowledge about guidelines for timely port and associated care processes; (2) minimize the burden of travel for hnscc care; (3) improve communication between patients and providers regarding intentions and goals for timely, guideline-adherent port; (4) enhance coordination of care between healthcare teams during care transitions and about treatment sequelae; (5) track referrals to ensure timely scheduling of appointments and patient attendance across fragmented healthcare systems; (6) restructure the organization to clarify roles and responsibilities for care processes associated with port delivery to avoid duplication and gaps in care. direct contact between the ndure navigator and patient occurs via three clinic-based, face-to-face ndure sessions lasting 30-60 minutes each. the three ndure sessions coincide with the pre-surgical consult, hospital discharge, and first postoperative visit, time points chosen to facilitate case identification and coordination across care transitions. during each ndure session, the navigator delivers patient education and creates or updates the port care plan. referral tracking and follow-up occurs through asynchronous contact between the navigator, patient, and healthcare organizations between ndure sessions. the sample size justification for this single-arm study is based on the primary feasibility endpoints of ndure accrual and completion. in the randomized controlled trial (rct) of ndure (nct04030130), the investigators plan to enroll 60% of eligible patients. the investigators expect similar accrual in this feasibility study and therefore, accruing to ndure will be considered feasible if at least 15 of 25 eligible subjects enroll. our sample size was selected to provide a small probability of having an observed accrual rate of at least 60% when the true accrual probability is actually less than 60%. for example, if the true accrual probability for our proposed design is 45% (35%), the probability of enrolling 15 or more of 25 eligible subjects is only 10% (1%). additionally, the investigators target an ndure completion rate ≥85%. that is to say, ndure is feasible if at least 13 of the 15 subjects enrolled complete all three in-person ndure sessions. accordingly, the sample size for the single-arm study was selected to provide a small probability of having an observed completion rate of at least 85% when the true completion probability of the intervention is actually less than 85%. for example, if the true completion probability for our proposed design is 70% (60%), the probability that 13 or more of the 15 enrolled patients complete all three in-person ndure sessions is 13% (3%). therefore, the probability of falsely declaring ndure feasible is reasonably controlled based on this sample size. statistical methods of analysis: this aim is descriptive, and the statistical analysis focuses on characterizing the feasibility and acceptability of ndure. to examine patterns and characterize sociodemographic, oncologic, and symptom burden variables, the investigators will construct graphical displays and descriptive statistics (e.g. frequencies and percent for categorical variables and mean, median, standard deviation, and range for continuous variables). feasibility measures for study accrual rate will evaluate the proportion and frequency of eligible patients who accrue (overall, white, and african american). given its pilot nature, the study is not designed to evaluate racial differences in accrual, although reasons for study decline will be collected, analyzed for each racial subgroup, and used to refine recruitment. ndure completion rate will be analyzed as 1) the percentage of enrolled patients who attend all three in-person ndure sessions and 2) the proportion of three in-person ndure sessions that are completed. for navigator caseload, the investigators will consider the frequency of simultaneous cases navigated. navigator time allocation for direct and indirect time, as well as patient-report measures of satisfaction with navigation will be summarized as described above for continuous data. study questionnaire completion rate will be calculated as the proportion of pre- and post-intervention questionnaires (n=5 each) completed. qualitative data will be analyzed using established team codebooks and focus on the content, format, delivery, and timing of ndure. qualitative analysis of semi-structured interviews with patients and providers following the pilot will be analyzed using established codebooks from the study team for evaluating the feasibility and acceptability of clinic-based interventions with a focus on the content, format, delivery, and timing of ndure.

Eligibility criteria:
inclusion criteria: patient and disease characteristics 1. age \> 18 years at the time of screening 2. histologically or pathologically confirmed invasive scc (or histologic variant) of the oral cavity, oropharynx (p16 positive, negative, or unknown), hypopharynx, larynx, unknown primary, paranasal sinuses, or nasal cavity. a. in situations in which the patient fulfills all other inclusion criteria but the biopsy shows scc in-situ or moderate/severe dysplasia (without definitive evidence of invasive scc), but the patient is scheduled to undergo curative intent surgery by the treating oncologic surgeon due to clinical suspicion of invasive scc, the diagnosis of scc-in situ or moderate/severe dysplasia is sufficient to full the pathologic diagnosis enrollment criterion. 3. american joint committee on cancer (ajcc) clinical stage grouping iii-iv (8th edition) for patients with scc of the oral cavity, p16-negative oropharynx, hypopharynx, larynx, paranasal sinuses, and nasal cavity; or ajcc clinical stage grouping iii-iv (7th edition) for patients with p16-positive scc of the oropharynx or unknown primary. 1. at screening, ajcc clinical stage grouping should be determined based on a combination of physical exam, diagnostic evaluation with cross sectional imaging of the neck (computerized tomography (ct) and/or magnetic resonance imaging (mri)) and/or 18-f-fluoro-deoxyglucose positron emission tomography (fdg pet) ct within 30 days 2. in situations in which the patient fulfills all other inclusion criteria but the biopsy shows scc in-situ or moderate/severe dysplasia (without definitive evidence of invasive scc), but would otherwise have an appropriate clinical stage grouping as defined in criterion 5, the diagnosis of scc-in situ or moderate/severe dysplasia is sufficient to full the staging enrollment criterion. 4. no prior exposure to radiation therapy, with or without concurrent chemotherapy, for treatment of hnscc in the definitive or adjuvant therapy settings surgery and adjuvant therapy eligibility 5. plan for curative intent surgery at musc a. at screening, plan for curative intent surgical resection of the hnscc at musc must be deemed likely by the treating surgeon and/or multidisciplinary tumor board, which must include a fellowship-trained head and neck oncologic surgeon 6. plan for port (at musc or non-musc) with or without concurrent chemotherapy following curative intent surgery a. at screening, plan for adjuvant therapy following curative intent surgical resection of the hnscc at musc must be deemed likely by the treating surgeon and/or multidisciplinary tumor board, which must include a fellowship-trained head and neck oncologic surgeon, based on the clinical expectation of at least one of the following adverse features on final pathologic evaluation: extranodal extension (ene), pathologic t3 or t4 primary, n2 or n3 nodal disease, nodal disease in levels iv or v, perineural invasion (pni), or lymphovascular invasion (lvi) exclusion criteria: 1. self-identified hispanic ethnicity 2. presence of cognitive impairment that precludes participation 3. failure to undergo curative intent surgery at musc 4. lack of indication for port (with or without concurrent chemotherapy) per national comprehensive cancer network (nccn) guidelines based on the presence of at least one of the following adverse features on final pathologic evaluation: ene, positive margin, pathologic stage t3 or t4 primary, pathologic stage n2 or n3 nodal disease, nodal disease in levels iv or v, perineurial invasion, or lymphovascular invasion 5. synchronous untreated malignancy